An interventional study of Tiotropium Inhalation Powder [Spiriva] 0.018mg and Salbutamol sulphate aerosol (Ventolin) 0.1mg in Airway Remodeling and Chronic Obstructive Pulmonary Disease, sponsored by Guangzhou Institute of Respiratory Disease. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Guangzhou Institute of Respiratory Disease · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized, open-label, three-arm clinical trial evaluated the effects of tiotropium on airway remodeling in patients with GOLD stage 1 COPD using endobronchial optical coherence tomography (EB-OCT). Participants were randomly assigned to receive tiotropium for 12 months followed by withdrawal for months 12-24, tiotropium continuously for 24 months, or SABA as needed without regular long-acting bronchodilator therapy. Airway morphology, pulmonary function, impulse oscillometry, and SABA use were assessed during the 24-month follow-up.
28 studies on the registry are indexed under Airway Remodeling; 5 are open to participants now.
This study's enrollment of 84 is above the median of 40 across 21 interventional studies indexed under Airway Remodeling.
Browse Airway Remodeling studies →Guangzhou Institute of Respiratory Disease is the lead sponsor of 99 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 21, 2026. See what changed
Key inclusion criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* During the 2 years treatment phase patients will be administered with tiotropium bromide (Spiriva) capsule 18μg once daily from baseline to the 12th months. * Scheduled tiotropium treatment was discontinued after month 12. Additional maintenance inhaled therapy was permitted if clinically indicated and was recorded. * Salbutamol sulphate aerosol (Ventolin) was available as needed for symptom relief throughout the 24-month follow-up.
Drug: Tiotropium Inhalation Powder [Spiriva] 0.018mg · Drug: Salbutamol sulphate aerosol (Ventolin) 0.1mg
* During the 2 years treatment phase patients will be administered with tiotropium bromide (Spiriva) capsule 18μg once daily from baseline to the 24th months. * Salbutamol sulphate aerosol (Ventolin) was available as needed for symptom relief throughout the 24-month follow-up.
Drug: Tiotropium Inhalation Powder [Spiriva] 0.018mg · Drug: Salbutamol sulphate aerosol (Ventolin) 0.1mg
* During the 24-month study period, salbutamol inhalation aerosol (Ventolin) was available as needed for symptom relief. * No scheduled long-acting bronchodilator was assigned in this group. Additional maintenance inhaled therapy was permitted if clinically indicated and was recorded.
Drug: Salbutamol sulphate aerosol (Ventolin) 0.1mg
Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.
Also known as: Spiriva
Salbutamol inhalation aerosol (Ventolin), 100 μg per actuation, was available as needed for symptom relief throughout the 24-month study period.
Also known as: Ventolin
Change from baseline in inner luminal area (Ai) of small airways (7th to 9th generation bronchi) at month 24
To evaluate the effects of tiotropium on structural remodeling of small airways in patients with early-stage COPD.
Time frame: Baseline and month 24
Change from baseline in inner luminal area (Ai) of small airways (7th to 9th generation bronchi) at month 12
Change from baseline to month 12 in patient-level mean airway luminal area of generations 7-9, measured by EB-OCT (mm²).
Time frame: Baseline and Month 12
Change from baseline in inner luminal area (Ai) of 3rd-6th generation bronchi
To evaluate the effects of tiotropium on structural remodeling of medium-sized airways in patients with early-stage COPD.
Time frame: Baseline, Month 12, and Month 24
Change from baseline in the airway wall area percentage (Aw%) of the 7th to 9th generation bronchi
To evaluate the effects of Tiotropium in ameliorating airway remodeling in early stage COPD
Time frame: Baseline, Month 12, and Month 24
Change from baseline in the airway wall area percentage (Aw%) of the 3rd to 6th generation bronchi
To evaluate the effects of Tiotropium in ameliorating airway remodeling in early stage COPD
Time frame: Baseline, Month 12, and Month 24
Change from baseline in trough FEV1
To evaluate the effects of Tiotropium in improving lung function
Time frame: Baseline, Month 12, and Month 24
Change from baseline in peripheral airway resistance (R5-R20)
To evaluate the effects of Tiotropium in improving lung function
Time frame: Baseline, Month 12, and Month 24
Change from baseline in COPD Assessment Test (CAT) score
Change from baseline in COPD Assessment Test (CAT) score
Time frame: Baseline, Month 12, and Month 24
Changes from baseline in parametric response mapping-defined functional small-airway disease and emphysema
Changes from baseline in parametric response mapping-defined functional small-airway disease and emphysema
Time frame: Baseline, month 12 and month 24
Proportion of participants experiencing at least one COPD exacerbation during 24 months
Proportion of participants experiencing at least one COPD exacerbation during the 24-month follow-up.
Time frame: Baseline to Month 24
Plan to share: Yes — Deidentified individual participant data underlying the published results may be shared upon reasonable request, subject to institutional approval, applicable consent restrictions, and a data-use agreement.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Deidentified participant-level data will be available upon reasonable request for five years following publication of the primary study results, subject to institutional approval and applicable data retention policies.
Access criteria: Requests should be directed to the corresponding author. Access will be considered for scientifically justified research proposals, subject to institutional approval, applicable consent restrictions, and execution of an appropriate data-use agreement.
No publications or documents are linked to this record.
Ran from Aug 2019 to primary completion in May 2025, 69 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Oct 2018 → Aug 2019, primary completion Dec 2022 → May 2025 and completion Dec 2022 → May 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tiotropium
Guangzhou Institute of Respiratory Disease